These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 28052331)
1. Computed Regioselectivity and Conjectured Biological Activity of Ene Reactions of Singlet Oxygen with the Natural Product Hyperforin. Abramova I; Rudshteyn B; Liebman JF; Greer A Photochem Photobiol; 2017 Mar; 93(2):626-631. PubMed ID: 28052331 [TBL] [Abstract][Full Text] [Related]
2. Instability of St. John's wort (Hypericum perforatum L.) and degradation of hyperforin in aqueous solutions and functional beverage. Ang CY; Hu L; Heinze TM; Cui Y; Freeman JP; Kozak K; Luo W; Liu FF; Mattia A; DiNovi M J Agric Food Chem; 2004 Oct; 52(20):6156-64. PubMed ID: 15453681 [TBL] [Abstract][Full Text] [Related]
3. The first prenylation step in hyperforin biosynthesis. Boubakir Z; Beuerle T; Liu B; Beerhues L Phytochemistry; 2005 Jan; 66(1):51-7. PubMed ID: 15649510 [TBL] [Abstract][Full Text] [Related]
4. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of β1 -adrenergic receptors in rat C6 glioblastoma cells by hyperforin and hyperoside from St John's wort. Jakobs D; Hage-Hülsmann A; Prenner L; Kolb C; Weiser D; Häberlein H J Pharm Pharmacol; 2013 Jun; 65(6):907-15. PubMed ID: 23647684 [TBL] [Abstract][Full Text] [Related]
6. Improved Bioactivity of the Natural Product 5-Lipoxygenase Inhibitor Hyperforin by Encapsulation into Polymeric Nanoparticles. Traeger A; Voelker S; Shkodra-Pula B; Kretzer C; Schubert S; Gottschaldt M; Schubert US; Werz O Mol Pharm; 2020 Mar; 17(3):810-816. PubMed ID: 31967843 [TBL] [Abstract][Full Text] [Related]
7. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790 [TBL] [Abstract][Full Text] [Related]
8. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112 [TBL] [Abstract][Full Text] [Related]
10. Hyperforin: To Be or Not to Be an Activator of TRPC(6). Friedland K; Harteneck C Rev Physiol Biochem Pharmacol; 2015; 169():1-24. PubMed ID: 26384487 [TBL] [Abstract][Full Text] [Related]
11. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis. Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821 [TBL] [Abstract][Full Text] [Related]
12. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin. Tadros MG; Mohamed MR; Youssef AM; Sabry GM; Sabry NA; Khalifa AE Behav Brain Res; 2009 May; 199(2):334-9. PubMed ID: 19136030 [TBL] [Abstract][Full Text] [Related]
13. Hyperforin, the active component of St. John's wort, induces IL-8 expression in human intestinal epithelial cells via a MAPK-dependent, NF-kappaB-independent pathway. Zhou C; Tabb MM; Sadatrafiei A; Grün F; Sun A; Blumberg B J Clin Immunol; 2004 Nov; 24(6):623-36. PubMed ID: 15622447 [TBL] [Abstract][Full Text] [Related]
15. Structural investigations of isomeric oxidised forms of hyperforin by HPLC-NMR and HPLC-MSn. Wolfender JL; Verotta L; Belvisi L; Fuzzati N; Hostettmann K Phytochem Anal; 2003; 14(5):290-7. PubMed ID: 14516001 [TBL] [Abstract][Full Text] [Related]
16. Mass spectral characterization of phloroglucinol derivatives hyperforin and adhyperforin. Sleno L; Daneshfar R; Eckert GP; Müller WE; Volmer DA Rapid Commun Mass Spectrom; 2006; 20(18):2641-8. PubMed ID: 16912989 [TBL] [Abstract][Full Text] [Related]
17. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug? Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950 [TBL] [Abstract][Full Text] [Related]
18. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts. Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201 [TBL] [Abstract][Full Text] [Related]
19. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Hokkanen J; Tolonen A; Mattila S; Turpeinen M Eur J Pharm Sci; 2011 Feb; 42(3):273-84. PubMed ID: 21168483 [TBL] [Abstract][Full Text] [Related]
20. Hypericin and hyperforin production in St. John's wort in vitro culture: influence of saccharose, polyethylene glycol, methyl jasmonate, and Agrobacterium tumefaciens. Pavlík M; Vacek J; Klejdus B; Kuban V J Agric Food Chem; 2007 Jul; 55(15):6147-53. PubMed ID: 17608493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]